Oncology

The primary end points of the EPCORE FL-1 trial were met while assessing an epcoritamab-based combination for patients with R/R follicular lymphoma.

Panelists discuss how voracidinib shows superior brain penetration compared to other IDH inhibitors and explore exciting combination approaches with i...

Immunocompromised individuals face ongoing COVID-19 risks despite vaccination, highlighting the need for tailored public health strategies and innovat...

An update of phase 1 data from the CTMX-2051-101 study is expected to be available by the first quarter of 2026.

Results from the phase 3 KEYNOTE-689 trial supported the agency’s approval of the pembrolizumab/surgery regimen in PD-L1–positive head and neck cancer...

Results from the SunRISe-1 trial showed that TAR-200 monotherapy achieved a complete response rate of 82.4% in patients with BCG-unresponsive NMIBC.

Ronald Bleday, MD, credits a chronic pain clinic for consulting patients who may be at a greater risk for prolonged opioid use following surgery.

Findings from the KRYSTAL-12 trial support adagrasib as a treatment option for those with disease progression on prior chemotherapy and immunotherapy.

Artificial intelligence is transforming healthcare, but doctors must balance its benefits with the risks, responsibilities, and legal safeguards. Med...

The development of nonnarcotic pain medication after GI surgery may help relieve chronic pain without the risk of opioid dependence.